tiprankstipranks
Zai Lab Reports Robust Q3 Growth and Pipeline Advances
Company Announcements

Zai Lab Reports Robust Q3 Growth and Pipeline Advances

Zai Lab Ltd (HK:9688) has released an update.

Don't Miss Our Christmas Offers:

Zai Lab Limited reported a 47% year-on-year increase in net product revenue for the third quarter of 2024, reaching $101.8 million, driven by the successful launch of VYVGART in China. The company continues to advance its pipeline with promising developments, including a positive China study for KarXT in schizophrenia and encouraging global Phase 1 data for ZL-1310 in small cell lung cancer. With a strong cash position and multiple product launches expected, Zai Lab is poised for future growth.

For further insights into HK:9688 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskZai Lab Ltd Issues Restricted Share Units to Employees
TheFlyMorning Movers: Intel climbs following retirement of CEO Pat Gelsinger
TheFlyZai Lab, Novocure announce PANOVA-3 trial met primary endpoint
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App